Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06602479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06602479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
October 7, 2024
Completion date
May 7, 2027
Enrollment
488 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

migraine